Cargando…

Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma

Detalles Bibliográficos
Autores principales:	Jamieson, Stephen M.F., Tsai, Peter, Kondratyev, Maria K., Budhani, Pratha, Liu, Arthur, Senzer, Neil N., Chiorean, E. Gabriela, Jalal, Shadia I., Nemunaitis, John J., Kee, Dennis, Shome, Avik, Wong, Way W., Li, Dan, Poonawala-Lohani, Nooriyah, Kakadia, Purvi M., Knowlton, Nicholas S., Lynch, Courtney R.H., Hong, Cho R., Lee, Tet Woo, Grénman, Reidar A., Caporiccio, Laura, McKee, Trevor D., Zaidi, Mark, Butt, Sehrish, Macann, Andrew M.J., McIvor, Nicholas P., Chaplin, John M., Hicks, Kevin O., Bohlander, Stefan K., Wouters, Bradly G., Hart, Charles P., Print, Cristin G., Wilson, William R., Curran, Michael A., Hunter, Francis W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2023
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990753/ https://www.ncbi.nlm.nih.gov/pubmed/36810255 http://dx.doi.org/10.1172/jci.insight.169136

Ejemplares similares

Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models
por: Harms, Julia K., et al.
Publicado: (2019)

Efficient identification of somatic mutations in acute myeloid leukaemia using whole exome sequencing of fingernail derived DNA as germline control
por: Kakadia, Purvi M., et al.
Publicado: (2018)

The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy
por: Nytko, Katarzyna J., et al.
Publicado: (2017)

Clinical remission following ascorbate treatment in a case of acute myeloid leukemia with mutations in TET2 and WT1
por: Das, Andrew B., et al.
Publicado: (2019)

(18)F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model
por: Grkovski, Milan, et al.
Publicado: (2018)

Deep-learning and MR images to target hypoxic habitats with evofosfamide in preclinical models of sarcoma
por: Jardim-Perassi, Bruna V., et al.
Publicado: (2021)

Emerging technologies for the genomic analysis of cancer
por: Nemunaitis, John, et al.
Publicado: (2009)

Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity
por: Spiegelberg, Linda, et al.
Publicado: (2019)

Letter to the editor: Does Dicer Expression Affect shRNA processing?
por: Senzer, Neil, et al.
Publicado: (2009)

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: let the virus be its own demise
por: Nemunaitis, John, et al.
Publicado: (2020)

Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo
por: Huang, Yan, et al.
Publicado: (2018)

Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide (TH‐302) in osteolytic breast cancer murine models
por: Liapis, Vasilios, et al.
Publicado: (2016)

Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma
por: Liapis, Vasilios, et al.
Publicado: (2017)

An ETV6-ABL1 fusion in a patient with chronic myeloproliferative neoplasm: Initial response to Imatinib followed by rapid transformation into ALL
por: Kakadia, Purvi M., et al.
Publicado: (2016)

Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models()
por: Kumar, Sushil, et al.
Publicado: (2018)

Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models
por: Stokes, Ashley M., et al.
Publicado: (2016)

Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer
por: Yoon, Jeesun, et al.
Publicado: (2021)

Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma
por: Brenner, Andrew J., et al.
Publicado: (2021)

Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced Disease
por: Simmons, Olivia, et al.
Publicado: (2012)

Procoagulant inhibitory properties of paclitaxel poliglumex
por: Nemunaitis, John, et al.
Publicado: (2010)

Circulating metabolites associated with tumor hypoxia and early response to treatment in bevacizumab-refractory glioblastoma after combined bevacizumab and evofosfamide
por: Lodi, Alessia, et al.
Publicado: (2022)

An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect()()
por: Hong, Cho Rong, et al.
Publicado: (2018)

Evofosfamide Is Effective against Pediatric Aggressive Glioma Cell Lines in Hypoxic Conditions and Potentiates the Effect of Cytotoxic Chemotherapy and Ionizing Radiations
por: Bailleul, Quentin, et al.
Publicado: (2021)

Patient-Derived Xenograft and Organoid Models for Precision Medicine Targeting of the Tumour Microenvironment in Head and Neck Cancer
por: Lee, Tet Woo, et al.
Publicado: (2020)

Derivation of Breast Cancer Cell Lines Under Physiological (5%) Oxygen Concentrations
por: Leung, Euphemia Y., et al.
Publicado: (2018)

A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug‐Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide
por: Lüpfert, Christian, et al.
Publicado: (2018)

A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model()()
por: Hajj, Carla, et al.
Publicado: (2017)

Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy
por: Alqahtani, Ali, et al.
Publicado: (2019)

Preclinical Assessment of wt GNE Gene Plasmid for Management of Hereditary Inclusion Body Myopathy 2 (HIBM2)
por: Jay, Chris, et al.
Publicado: (2008)

(18)F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition
por: Reeves, Kirsten M., et al.
Publicado: (2022)

FHL2 interacts with CALM and is highly expressed in acute erythroid leukemia
por: Pašaliç, Z, et al.
Publicado: (2011)

A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients
por: Larue, Ruben T. H. M., et al.
Publicado: (2016)

Tumor hypoxia drives immune suppression and immunotherapy resistance
por: Ai, Midan, et al.
Publicado: (2015)

Safety and in vivo Expression of a GNE-Transgene: A Novel Treatment Approach for Hereditary Inclusion Body Myopathy-2
por: Phadke, Anagha P., et al.
Publicado: (2009)

KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex
por: Rao, Donald D., et al.
Publicado: (2018)

Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma
por: Ghisoli, Maurizio, et al.
Publicado: (2015)

Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma
por: Rao, Donald D., et al.
Publicado: (2016)

Medical educators’ beliefs about learning goals, teaching, and assessment in the context of curriculum changes: a qualitative study conducted at an Iranian medical school
por: Karami, Morteza, et al.
Publicado: (2021)

1716P Vigil plasmid (VP), a dual bi-shRNA-furin/GMCSF construct from cancer to SARS-CoV-2
por: Jay, C., et al.
Publicado: (2020)

Impact of diabetic retinopathy on pulse wave analysis-derived arterial stiffness and hemodynamic parameters: A cross-sectional study from Gujarat, India
por: Solanki, Jayesh D, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_roitdcvcvsg0jr7r0btb5r2tf7